期刊文献+

pEGFC1-IGFBP7诱导恶性黑素瘤SK-MEL-28细胞的凋亡 被引量:3

pEGFC1-IGFBP7 induces apoptosis of malignant melanoma cell line SK-MEL-28
下载PDF
导出
摘要 目的:构建胰岛素样生长因子结合蛋白7(insulin-like growth factor binding protein7,IGFBP7)表达质粒(pEGFC1-IGFBP7),研究IGFBP7对恶性黑素瘤细胞SK-MEL-28凋亡的影响。方法:构建pEGFC1-IGFBP7质粒,并将pEGFC1-IGFBP7质粒及空质粒分别转染入SK-MEL-28细胞,荧光显微镜观测细胞转染效率,Annexin-FITC/PI检测转染后SK-MEL-28细胞的凋亡。结果:成功构建pEGFC1-IGFBP7质粒,用Effectene试剂能将pEGFC1-IGFBP7质粒有效转染入SK-MEL-28细胞,转染效率达61%。流式细胞仪结果显示pEGFC1-IGFBP7可明显促进SK-MEL-28细胞凋亡,转染24h后的凋亡率达(28.4±2.57)%,转染空质粒及未转染组细胞凋亡率分别为(5.8±0.44)%和(6.4±0.71)%(F=406.138,P<0.05)。结论:pEGFC1-IGFBP7能有效诱导黑素瘤SK-MEL-28细胞凋亡,为IGFBP7为基础的黑素瘤基因治疗提供了实验依据。 Objective:To construct the insulin-like growth factor binding protein 7 (IGFBP7) expression plasmid (pEGFC1-IGFBP7) and to investigate the effect of IGFBP7 on the apoptosis of SK-MEL-28 (human malignant melanoma cell line) cells.Methods:The pEGFC1-IGFBP7 plasmid was constructed;pEGFC1-IGFBP7 and empty plasmids were transfected into SK-MEL-28 cells separately.The transfection efficiency was observed under fluorescence microscope.Apoptosis of SK-MEL-28 cells after transfection was detected by Annexin-FITC/PI staining.Results:The pEGFC1-IGFBP7 plasmid was successfully constructed and was effectively transfected into SK-MEL-28 cells by Effectene reagent,with the transfection rate being 61%.The results of flow cytometry showed that pEGFC1-IGFBP7 significantly induced apoptosis of SK-MEL-28 cells,with the apoptotic rates of pEGFC1-IGFBP7,empty vector,and non-transfected plasmid groups being (28.4±2.57)%,(5.8±0.44)%,and (6.4±0.71)% 24 h after transfection,respectively (F=406.138,P〈0.05).Conclusion:pEGFC1-IGFBP7 can effectively induce apoptosis of malignant melanoma SK-MEL-28 cells,which provides an experimental basis for IGFBP7 gene-based therapy of malignant melanoma.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2010年第1期36-39,共4页 Chinese Journal of Cancer Biotherapy
基金 国家教育部新教师基金资助项目(No.20070487140)~~
关键词 胰岛素样生长因子结合蛋白7(IGFBP7) 黑素瘤 SK-MEL-28细胞 凋亡 insulin-like growth fator binding protein 7(IGFBP7) melanoma SK-MEL-28 cell apoptosis
  • 相关文献

参考文献2

二级参考文献19

  • 1Nencioni A,Brossart P.Cellular immunotherapy with dendritic cells in cancer:current status[J].Stem Cells,2004,22(4):501-513. 被引量:1
  • 2Small EJ,Schellhammer PF,Higano CS,et al.Placebo-controlled phase Ⅲ trial of immunologic therapy with sipuleucel-T(APC8015)in patients with metastatic,asymptomatic hormone refractory prostate cancer[J].J Clin Oncol,2006,24(19):3089-3094. 被引量:1
  • 3Schadendorf D,Ugurel S,Schuler-Thurner B,et al.Dacarbazine(DTIC)versus vaccination with autologous peptide-pulsed dendritic cells(DC)in first-line treatment of patients with metastatic melanoma:a randomized phase Ⅲ trial of the DC study group of the DeCOG[J].Ann Oncol,2006,17(4):563-570. 被引量:1
  • 4Ovali E,Dikmen T,Sonmez M,et al.Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine:a safety study[J].J Exp Clin Cancer Res,2007,26(2):209-214. 被引量:1
  • 5Steinman RM.The dendritic cell system and its role in immunogenicity[J].Annu Rev Immunol,1991,9:271-296. 被引量:1
  • 6Shuler G,Schuler-Thurner B,Steinman RM.The use of dendritic cells in cancer immunotherapy[J].Curr Opin Immunol,2003,15(2):138-147. 被引量:1
  • 7Tuettenberg A,Becker C,Huter E,et al.Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage Ⅱ melanoma patients[J].Int J Cancer,2006,118(10):2617-2627. 被引量:1
  • 8Mullins DW,Sheasley SL,Ream RM,et al.Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control[J].J Exp Med,2003,198(7):1023-1034. 被引量:1
  • 9Bedrosian I,Mick R,Xu S,et al.Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients[J].J Clin Oncol,2003,21(20):3826-3835. 被引量:1
  • 10Kato,M.V.A secreted tumor-suppressor, mac25, with activin-binding activity[].Mol Med.2000 被引量:1

共引文献15

同被引文献26

  • 1Wajapeyee N, Serra R W, Zhu X, et al. Oncogenic BRAF induces senescence and apoptosis through pathways media- ted by the secreted protein IGFBP7[J]. Cell, 2008, 132(3): 363-374. 被引量:1
  • 2Chen R Y, Chen H X, Lin J X, et al. In-vivo transfection of pcDNA3.1-IGFBP7inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression[J]. J Exp Clin Cancer Res. 2010,29:13. 被引量:1
  • 3Chen R Y, Chen H X, Jian P, et al. Intratumoral injection of pEGFCI-IGFBP7 inhibits malignant melanoma growth in C57BL/6J mice by inducing apoptosis and down-regulating VEGF expression[J]. Oncol Rcp. 2010,23(4):981-988. 被引量:1
  • 4Tamura K, Hashimoto K, Suzuki K, et al. Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothe- lial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells[J]. Eur J Phannacol, 2009, 610(1-3):61-67. 被引量:1
  • 5Kanemitsu N, Kato M V, Mild T, et al. Characterization of the promoter of the murine mac25 gene[J]. Bioehem Biophys Res Commtm, 2000, 279(1):251-257. 被引量:1
  • 6Bustin S A, Jenkins P I. The growth hormone-insulin-like growth factor-I axis and colorectal cancer[J]. Trends Mol Med, 2001, 7(10):447-454. 被引量:1
  • 7Di Popolo A, Memoli A, Apicella A, et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells[J]. Oncogene, 2000,19(48):5517-5524. 被引量:1
  • 8Burger A M, Leyland-Jones B, Banerjee K, et al. Essential roles of !GFBP-3 and IGFBP-rP1 in breast eaneer[J].Eur J Cancer, 2005, 41(11):1515-1527. 被引量:1
  • 9Sato Y, Chen Z, Miyazald K. Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/mac25[J]. Cancer Sci, 2007,98(7): 1055-1063. 被引量:1
  • 10Sharma A, Trivedi N R, Zimmerman M A, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors[J].Cancr Rcs, 2005, 65(6): 2412-2421. 被引量:1

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部